Global Acute Migraine Drugs Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	122 Pages	DataM Intelligence 4Market Research LLP	August, 2023	DTAM18096286

Best Price Guarantee
Price	from $4,350
Length	122 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	August, 2023
SKU	DTAM18096286

Global Acute Migraine Drugs Market - 2023-2030

Global Acute Migraine Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 4.5 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2023-2030. The growing clinical trials for novel drugs are driving up demand for acute migraine drugs market trends.

The global acute migraine drugs market experiencing significant growth in recent years. There have been significant advancements in the development of new therapies for acute migraine treatment. These monoclonal antibodies, such as erenumab, fremanezumab, and galcanezumab, have gained approval as preventive treatments and are also being explored for their potential use in acute migraine treatment. The market is highly competitive, with several key players actively involved in the research, development, and commercialization of acute migraine drugs.

The global acute migraine drugs market is driven by the factors such as the increasing prevalence of migraine, rising demand for innovative drugs, increasing awareness and diagnosis, and technological advancements in acute migraine drugs.

Market Dynamics
Rising Demand for Innovative Drugs Drives the Growth of the Acute Migraine Drugs Market
The demand for innovative drugs is also driven by the desire for more convenient and effective treatment modalities. The development of novel drug delivery systems, such as nasal sprays, injectable formulations, and transdermal patches, aims to enhance drug efficacy, improve patient compliance, and provide faster relief from migraine symptoms. These advancements contribute to market growth by meeting the evolving needs and preferences of patients.

Migraine is a complex neurological disorder, and there is a continuous need for more effective and targeted treatments to alleviate symptoms and improve patient outcomes. And the rising clinical trials leading to innovative drugs for the better treatment of acute migraine.

For instance, on June 13, 2023, Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company’s five rapid-onset investigational neuroactive pherine therapeutics.

Increasing Awareness and Diagnosis Also Drive the Growth of the Acute Migraine Drugs Market
With increased awareness, individuals are more likely to seek medical help at the onset of migraine symptoms, leading to earlier intervention and treatment. Early treatment is associated with better outcomes, as it can help alleviate symptoms faster and potentially prevent the progression of migraines. The emphasis on early intervention fuels the demand for acute migraine drugs that provide rapid relief during migraine attacks.

As awareness of migraines grows, healthcare providers are increasingly educated about the diagnosis and management of the condition. Medical societies and organizations publish guidelines and recommendations for the treatment of migraines, emphasizing evidence-based approaches. These guidelines influence physicians' prescribing patterns, contributing to the increased utilization of acute migraine drugs.

High Cost of Drugs will Hamper the Growth of the Market
The high cost of drugs can make them inaccessible to a significant portion of the population, especially those without adequate health insurance coverage or limited financial resources. This can create barriers to access and prevent individuals from receiving appropriate treatment for their migraines. The affordability of drugs is a crucial factor in ensuring that patients can obtain the medications they need.

High drug costs can pose challenges in terms of reimbursement and insurance coverage. Insurance providers may have strict coverage policies or high co-payment requirements for expensive migraine drugs, limiting patient access. This can lead to delays in receiving treatment or even the use of less effective or more affordable alternatives, impacting patient outcomes.

COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global acute migraine drugs market. Clinical trials for new acute migraine drugs may have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limitations on on-site visits, and prioritization of COVID-19-related research affected the progression of clinical trials. These delays may have impacted the introduction of new treatments to the market.

Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute migraine drugs market. The conflict can lead to disruptions in supply chains, including the transportation of pharmaceutical products and raw materials for acute migraine drugs. Border closures, trade restrictions, and increased security measures can impede the movement of goods, potentially causing delays or shortages in the availability of acute migraine drugs.

Segment Analysis
The global acute migraine drugs market is segmented based on drug type, route of administration, distribution channel, and region.

Triptans from the Drug Type Segment Accounts for 36.8% of the Acute Migraine Drugs Market Share
Triptans are available in various formulations and administration routes, allowing for flexibility and individualized treatment approaches. Oral tablets, nasal sprays, injectable formulations, and dissolving tablets offer different options for patients with acute migraine. The availability of different triptan options enhances patient convenience and increases the likelihood of finding a suitable treatment method, further enhancing market dominance.

Some triptan drugs have gained significant brand recognition and loyalty among healthcare providers and patients. Well-known brands have established themselves as trusted options, with physicians often prescribing them due to their familiarity and proven track record. This brand recognition and loyalty contribute to the continued dominance of triptans in the acute migraine drugs market.

Geographical Analysis
North America Accounted for Approximately 40.2% of the Market Share Owing to the Strong Research and Developments and Advanced Healthcare Infrastructure

North America boasts advanced healthcare infrastructure, including well-established healthcare systems, medical facilities, and research institutions. These resources support the development, approval, and distribution of acute migraine drugs. The region's robust healthcare infrastructure enables access to innovative treatments including drugs, and enhances clinical trials for innovative drugs.

North America has a strong focus on research and development activities in the pharmaceutical industry. The region is home to numerous pharmaceutical companies, academic institutions, and research organizations that actively contribute to the development of new acute migraine drugs. The presence of these entities and the availability of funding for research and development initiatives drive innovations further enhancing the market growth in the region.

For instance, on November 16, 2022, AbbVie announced that Health Canada has approved UBRELVY (ubrogepant tablet) for the acute treatment of migraine, with or without aura, in adults. UBRELVY is the first orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.

Competitive Landscape
The major global players in the acute migraine drugs market include Teva Pharmaceuticals, F Hoffmann-la Roche Ltd, Johnson & Johnson, Pfizer Inc., AstraZeneca, Amgen Inc., Merck & Co., Novartis AG, Eli lilly and Company, and Sun Pharma.

Why Purchase the Report?
• To visualize the global acute migraine drugs market segmentation based on drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of acute migraine drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global acute migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Drug Type; 3.2. Snippet by Route of Administration; 3.3. Snippet by Distribution Channel; 3.4. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Rising Demand for Innovative Drugs; 4.1.1.2. Increasing Awareness and Diagnosis; 4.1.2. Restraints; 4.1.2.1. High Cost of the Drugs; 4.1.3. Opportunity; 4.1.3.1. Technological Advancements and Novel Drug Launches; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter’s 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Scenario Post COVID-19; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturer’s Strategic Initiatives; 6.6. Conclusion
7. By Drug Type: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 7.1.2. Market Attractiveness Index, By Drug Type; 7.2. Triptans *; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. NSAIDs; 7.4. Ergot Alkaloids; 7.5. Others
8. By Route of Administration: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.1.2. Market Attractiveness Index, By Route of Administration; 8.2. Oral *; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Parenteral; 8.4. Nasal; 8.5. Others
9. By Distribution Channel: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 9.1.2. Market Attractiveness Index, By Distribution Channel; 9.2. Hospital Pharmacies *; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Retail Pharmacies; 9.4. Online Pharmacies
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.6.1. U.S.; 10.2.6.2. Canada; 10.2.6.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.6.1. Germany; 10.3.6.2. U.K.; 10.3.6.3. France; 10.3.6.4. Spain; 10.3.6.5. Italy; 10.3.6.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.6.1. Brazil; 10.4.6.2. Argentina; 10.4.6.3. Rest of South America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.6.1. China; 10.5.6.2. India; 10.5.6.3. Japan; 10.5.6.4. Australia; 10.5.6.5. Rest of Asia-Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis
12. Company Profiles: 12.1. Teva Pharmaceuticals *; 12.1.1. Company Overview; 12.1.2. Product Portfolio and Description; 12.1.3. Financial Overview; 12.1.4. Key Developments; 12.2. F Hoffmann-la Roche Ltd; 12.3. Johnson & Johnson; 12.4. Pfizer Inc.; 12.5. AstraZeneca; 12.6. Amgen Inc.; 12.7. Merck & Co.; 12.8. Novartis AG; 12.9. Eli Lilly and Company; 12.10. Sun Pharma; LIST NOT EXHAUSTIVE
13. Appendix: 13.1. About Us and Services; 13.2. Contact Us